CU24522B1 - PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS - Google Patents
PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDASInfo
- Publication number
- CU24522B1 CU24522B1 CU2019000010A CU20190010A CU24522B1 CU 24522 B1 CU24522 B1 CU 24522B1 CU 2019000010 A CU2019000010 A CU 2019000010A CU 20190010 A CU20190010 A CU 20190010A CU 24522 B1 CU24522 B1 CU 24522B1
- Authority
- CU
- Cuba
- Prior art keywords
- alkylsulfonylpiperidin
- fluoroalkyl
- pyrimidin
- onas
- pyrid
- Prior art date
Links
- -1 AMINO Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p>Esta invención se relaciona con compuestos de tipo pirido[2,3-d]pirimidin-7(8h)-onas 6-fluoroalquil-2-(alquilsulfonilpiperidin-4-il)amino sustituidas, de la fórmula general (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>útiles para tratar y reducir trastornos proliferativos de células anormales, tales como cáncer.</p> <p> </p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371602P | 2016-08-15 | 2016-08-15 | |
| US201762533347P | 2017-07-17 | 2017-07-17 | |
| PCT/IB2017/054655 WO2018033815A1 (en) | 2016-08-15 | 2017-07-31 | Pyridopyrimdinone cdk2/4/6 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20190010A7 CU20190010A7 (es) | 2019-10-04 |
| CU24522B1 true CU24522B1 (es) | 2021-06-08 |
Family
ID=59631834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2019000010A CU24522B1 (es) | 2016-08-15 | 2017-07-31 | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS |
Country Status (43)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109803968A (zh) * | 2016-08-15 | 2019-05-24 | 辉瑞公司 | 吡啶并嘧啶酮cdk2/4/6抑制剂 |
| JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| JP2020097562A (ja) | 2018-09-25 | 2020-06-25 | ファイザー・インク | ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オンの合成 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
| WO2020148635A1 (en) * | 2019-01-17 | 2020-07-23 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
| US20200316064A1 (en) * | 2019-02-15 | 2020-10-08 | Incyte Corporation | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11203594B2 (en) * | 2019-04-19 | 2021-12-21 | Pfizer Inc. | Anti-proliferative agents for treating PAH |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020240360A1 (en) * | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
| WO2021014360A1 (en) | 2019-07-23 | 2021-01-28 | Pfizer Inc. | Oral modified release dosage forms |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| AU2020364007A1 (en) * | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US20240190861A1 (en) * | 2019-10-17 | 2024-06-13 | Cisen Pharmaceutical Co., Ltd | Aminopyrimidine compound as cdk2/4/6 triple inhibitor |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| JP2023515629A (ja) * | 2020-02-28 | 2023-04-13 | フォチョン・バイオサイエンシーズ・リミテッド | Ｃｄｋ２／４／６阻害剤としての化合物 |
| TW202146017A (zh) * | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| CN113773315A (zh) * | 2020-06-10 | 2021-12-10 | 无锡佰翱得生物科学有限公司 | 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂 |
| CN115702155B (zh) * | 2020-06-17 | 2025-01-24 | 微境生物医药科技(上海)有限公司 | 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 |
| WO2022015670A1 (en) * | 2020-07-14 | 2022-01-20 | Nikang Therapeutics, Inc. | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
| SI4214202T1 (sl) | 2020-09-15 | 2025-05-30 | Pfizer Inc. | Trdne oblike inhibitorja cdk4 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022140472A1 (en) * | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022152259A1 (zh) * | 2021-01-15 | 2022-07-21 | 江苏先声药业有限公司 | Cdk2/4/6抑制剂及其制备方法和应用 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN116456987A (zh) * | 2021-06-09 | 2023-07-18 | 郑州同源康医药有限公司 | 用作cdk激酶抑制剂的化合物及其应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023281413A1 (en) | 2021-07-09 | 2023-01-12 | Pfizer Inc. | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |
| CN116390921A (zh) * | 2021-09-29 | 2023-07-04 | 中国医药研究开发中心有限公司 | 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| EP4433061A4 (en) * | 2021-11-18 | 2025-09-03 | Onconova Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| US20250163063A1 (en) * | 2022-01-25 | 2025-05-22 | Kinnate Biopharma Inc. | Inhibitors of cdk4/6 kinase |
| CN119451967A (zh) * | 2022-06-22 | 2025-02-14 | 霖康疗法公司 | 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物的双功能化合物 |
| WO2024039903A2 (en) * | 2022-08-19 | 2024-02-22 | Kymera Therapeutics, Inc. | Cdk2 inhibitors and uses thereof |
| CN120379671A (zh) | 2022-10-18 | 2025-07-25 | 辉瑞公司 | 用于治疗癌症的化合物 |
| WO2024173766A1 (en) * | 2023-02-17 | 2024-08-22 | Differentiated Therapeutics, Inc. | Cyclin dependent kinase degraders and methods of use thereof |
| IL324946A (en) | 2023-06-01 | 2026-01-01 | H Lundbeck As | Spiro-macrocyclic orexin 2 receptor agonists |
| WO2025175258A1 (en) * | 2024-02-17 | 2025-08-21 | Padarn Therapeutics, Inc. | Inhibitors of cdk2 |
| WO2025207957A1 (en) * | 2024-03-28 | 2025-10-02 | Yale University | Small-molecule pi5p4k alpha/beta inhibitors and methods using same |
| CN120842218A (zh) * | 2024-04-26 | 2025-10-28 | 郑州同源康医药有限公司 | 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| US6413971B1 (en) | 1996-11-27 | 2002-07-02 | Pfizer Inc | Fused bicyclic pyrimidine derivatives |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| KR20020070520A (ko) * | 2000-01-27 | 2002-09-09 | 워너-램버트 캄파니 | 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체 |
| PL358271A1 (pl) | 2000-03-06 | 2004-08-09 | Warner-Lambert Company | 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny |
| DE60206363T2 (de) | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| US6951769B2 (en) | 2003-06-04 | 2005-10-04 | Texas Instruments Incorporated | Method for stripping sacrificial layer in MEMS assembly |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| BRPI0507852A (pt) | 2004-02-18 | 2007-07-10 | Warner Lambert Co | 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| CN101395155A (zh) * | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| BRPI0716880A2 (pt) | 2006-09-08 | 2013-10-15 | Pfizer Prod Inc | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| DK2074122T5 (da) * | 2006-09-15 | 2014-03-17 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| JP2010523670A (ja) * | 2007-04-10 | 2010-07-15 | エクセリクシス， インク． | Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 |
| WO2009132980A1 (en) * | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | Pyrimidinyl pyridone inhibitors of jnk. |
| WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| JP2012505927A (ja) | 2008-10-22 | 2012-03-08 | エフ．ホフマン−ラ ロシュ アーゲー | Ｊｎｋのピリミジニルピリドン阻害剤 |
| US20140163026A1 (en) * | 2011-04-08 | 2014-06-12 | Afraxis Holdings, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer |
| TW201311683A (zh) * | 2011-04-29 | 2013-03-16 | Exelixis Inc | 使用吡啶并嘧啶酮ｐｉ３ｋ／ｍｔｏｒ抑制劑治療淋巴瘤之方法 |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| CN104271576A (zh) * | 2012-02-23 | 2015-01-07 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
| SI2958916T1 (sl) | 2013-02-21 | 2018-11-30 | Pfizer Inc. | Trdne oblike selektivnih zaviralcev CDK4/6 |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| EP3076789A4 (en) * | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| US9734210B2 (en) | 2014-07-31 | 2017-08-15 | Linkedin Corporation | Personalized search based on searcher interest |
| CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| CN109803968A (zh) * | 2016-08-15 | 2019-05-24 | 辉瑞公司 | 吡啶并嘧啶酮cdk2/4/6抑制剂 |
-
2017
- 2017-07-31 CN CN201780063655.5A patent/CN109803968A/zh active Pending
- 2017-07-31 SG SG11201900799XA patent/SG11201900799XA/en unknown
- 2017-07-31 MX MX2019001849A patent/MX389597B/es unknown
- 2017-07-31 CU CU2019000010A patent/CU24522B1/es unknown
- 2017-07-31 WO PCT/IB2017/054655 patent/WO2018033815A1/en not_active Ceased
- 2017-07-31 LT LTEP17752493.1T patent/LT3497103T/lt unknown
- 2017-07-31 PT PT177524931T patent/PT3497103T/pt unknown
- 2017-07-31 SI SI201730793T patent/SI3497103T1/sl unknown
- 2017-07-31 UA UAA201900905A patent/UA124804C2/uk unknown
- 2017-07-31 ES ES17752493T patent/ES2876411T3/es active Active
- 2017-07-31 MA MA45920A patent/MA45920B1/fr unknown
- 2017-07-31 AU AU2017311645A patent/AU2017311645B2/en not_active Ceased
- 2017-07-31 HU HUE17752493A patent/HUE055978T2/hu unknown
- 2017-07-31 MY MYPI2019000748A patent/MY198534A/en unknown
- 2017-07-31 BR BR112019002610A patent/BR112019002610A2/pt active Search and Examination
- 2017-07-31 JP JP2019507917A patent/JP6563623B1/ja not_active Expired - Fee Related
- 2017-07-31 PL PL17752493T patent/PL3497103T3/pl unknown
- 2017-07-31 RU RU2019104087A patent/RU2726115C1/ru active
- 2017-07-31 GE GEAP201714998A patent/GEP20217234B/en unknown
- 2017-07-31 HR HRP20210871TT patent/HRP20210871T1/hr unknown
- 2017-07-31 PE PE2019000359A patent/PE20190475A1/es unknown
- 2017-07-31 DK DK17752493.1T patent/DK3497103T3/da active
- 2017-07-31 CN CN202210092651.2A patent/CN114394966B/zh active Active
- 2017-07-31 EP EP17752493.1A patent/EP3497103B1/en active Active
- 2017-07-31 KR KR1020197007466A patent/KR102236605B1/ko not_active Expired - Fee Related
- 2017-07-31 MD MDE20190682T patent/MD3497103T2/ro unknown
- 2017-07-31 NZ NZ750410A patent/NZ750410A/en unknown
- 2017-07-31 TN TNP/2019/000039A patent/TN2019000039A1/en unknown
- 2017-07-31 CA CA2975033A patent/CA2975033C/en active Active
- 2017-07-31 RS RS20210691A patent/RS61934B1/sr unknown
- 2017-07-31 CR CR20190062A patent/CR20190062A/es unknown
- 2017-07-31 US US15/664,265 patent/US10233188B2/en active Active
- 2017-08-02 TW TW106126113A patent/TWI663169B/zh not_active IP Right Cessation
- 2017-08-04 UY UY0001037352A patent/UY37352A/es not_active Application Discontinuation
-
2019
- 2019-01-17 US US16/251,032 patent/US10800783B2/en active Active
- 2019-02-04 ZA ZA2019/00716A patent/ZA201900716B/en unknown
- 2019-02-06 IL IL264687A patent/IL264687B/en active IP Right Grant
- 2019-02-11 NI NI201900013A patent/NI201900013A/es unknown
- 2019-02-12 CO CONC2019/0001240A patent/CO2019001240A2/es unknown
- 2019-02-12 CL CL2019000368A patent/CL2019000368A1/es unknown
- 2019-02-14 DO DO2019000030A patent/DOP2019000030A/es unknown
- 2019-02-14 EC ECSENADI201911216A patent/ECSP19011216A/es unknown
- 2019-02-15 SV SV2019005836A patent/SV2019005836A/es unknown
- 2019-02-15 PH PH12019500329A patent/PH12019500329A1/en unknown
-
2020
- 2020-08-27 US US17/005,233 patent/US11396512B2/en active Active
-
2021
- 2021-06-07 CY CY20211100495T patent/CY1124206T1/el unknown
-
2022
- 2022-06-15 US US17/841,138 patent/US20220324872A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24522B1 (es) | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS | |
| MX2012004157A (es) | 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. | |
| NI201900061A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| NI201900060A (es) | Inhibidores de moléculas pequeñas de la familia de quinasa jak | |
| NI201800128A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| TW201613925A (en) | Imidazopyrazines as LSD1 inhibitors | |
| NI201700095A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| BR112018005851A2 (pt) | derivados de pirrolo[2,3-d]pirimidina como inibidores de dyrk1 / clk1 duais | |
| EP2580214A4 (en) | 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS | |
| MX385450B (es) | Procedimiento para la preparación de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo. | |
| MX2013011518A (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer. | |
| AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
| CO2018005163A2 (es) | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| NZ763737A (en) | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins | |
| DK3489238T3 (da) | Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser | |
| JOP20140141B1 (ar) | استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية | |
| ECSP17038100A (es) | Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas | |
| MA50375A (fr) | Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 | |
| MX385576B (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2 | |
| MX2016015762A (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor. | |
| CU24402B1 (es) | 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como cáncer | |
| NI201800043A (es) | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 | |
| PE20190778A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida | |
| MX382774B (es) | Procesos para preparar un inhibidor de fgfr |